Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

NCT02319837 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02319837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02319837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 17, 2014
Completion date
September 19, 2026
Enrollment
1,068 (actual)
Sites
255

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, hormone sensitive prostate cancer, prostate cancer